The Bill & Melinda Gates Foundation is to make a $55 million equity investment in BioNTech SE as part of a collaboration aimed at developing potential HIV and tuberculosis vaccine and immunotherapy candidate drugs. Total funding under the collaboration could reach $100 million through potential future grant funding from the Gates Foundation. The additional funds would be used to underwrite the evaluation of the candidate products in the clinic and to start new infectious disease projects.
